Andres Ricaurte-Fajardo: Advances in PSMA-Targeted Radionuclide Therapeutics
Andres Ricaurte-Fajardo, Neurology resident at Pontifical Javeriana University, shared an article by Samuel Ruder, et al. on LinkedIn:
“Thrilled to share that our latest review “Advances in PSMA-Targeted Radionuclide Therapeutics” has just been published in Current Treatment Options in Oncology, a Q1 journal in the field!
This work explores one of the most promising frontiers in precision oncology: PSMA-targeted radionuclide therapies for prostate cancer, including the FDA-approved 177Lu-PSMA-617.
Some key takeaways:
- PSMA-TRT has shown significant survival benefits in patients with metastatic castration-resistant prostate cancer, as demonstrated in the VISION trial.
- Promising results are emerging for earlier-stage patients, potentially delaying or avoiding chemotherapy.
- We dive into cutting-edge combinations with PARP inhibitors, immunotherapy, and chemotherapy, as well as alpha-emitters like 225Ac and novel delivery mechanisms (PSMA-I&T, SAR-bis-PSMA, and mAbs).
- Future success hinges on patient selection, dosimetry, and the integration of predictive biomarkers.
This paper represents a collective effort to spotlight the therapeutic potential of molecular imaging and radioligand therapy in prostate cancer.
Thanks to Drs. Samuel Ruder, Michael Sun, Scott Tagawa, Joseph Osborne, Sandra Huicochea Castellanos for your help and support.
Read full paper here.”
Advances in PSMA-Targeted Radionuclide Therapeutics.
Authors: Samuel Ruder, et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023